Detect™ Selected by NIH to Scale Manufacturing of PCR-Quality Rapid At-Home Covid-19 Test
Retrieved on:
Thursday, October 14, 2021
Biotechnology, FDA, Infectious Diseases, Health, Clinical Trials, Travel, COVID-19 testing, COVID-19, Technology, Program, NAAT, Medical imaging, Tech, STI, National Institute, Department, Test Tube Aliens, Biological engineering, Delta, Therapy, School, Marketing, NYSE, FDA, Multimedia, Detectives Inc., Health, COVID-19 contracts in the United Kingdom, Food and Drug Administration, National Medal of Technology and Innovation, Human services, National, National Medal, National Institute of Biomedical Imaging and Bioengineering, Test tube, Food, Â, Hyperfine structure, NIH, Review, Innovation, Partnership, Nursing, Butterfly network, Acceleration, United States Department of Health and Human Services, Pharmaceutical industry
The $8.1 million contract will facilitate the development and scale up manufacturing of Detects PCR-quality rapid at-home Covid-19 test to meet national testing demand.
Key Points:
- The $8.1 million contract will facilitate the development and scale up manufacturing of Detects PCR-quality rapid at-home Covid-19 test to meet national testing demand.
- View the full release here: https://www.businesswire.com/news/home/20211014006048/en/
The Detect Covid-19 Test provides PCR-quality results for use at home in approximately one hour. - The test includes a reusable Detect Hub (sold separately), a Detect Test Reader, a Dropper pre-filled with buffer, a nasal swab designed by Detect, a Test Tube with pre-filled liquid buffer and a proprietary reagent bead that dissolves in the Test Tube liquid.
- The Detect Covid-19 Test is specifically designed for large-scale, low-cost manufacturing, which sets it apart from other molecular tests on the market today.